Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News EuroPCR 2016

LAA Closure May Provide Solution for Stroke Prevention in Patients With Prior Intracerebral Hemorrhage

Yael L. Maxwell

May 18, 2016

News Conference News EuroPCR 2016

Last Window for BMS Closes as LEADERS-FREE Supports DES in High-Bleeding-Risk ACS

Michael O'Riordan

May 17, 2016

News Conference News EuroPCR 2016

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

Yael L. Maxwell

May 17, 2016

News Conference News EuroPCR 2016

‘Signal’ of Poor Durability Seen With First-Generation TAVR Devices

Caitlin E. Cox

May 17, 2016

News Conference News EuroPCR 2015

DEFLECT III: 30-Day Results Show Successful, Safe TAVR With Novel Neuroprotection Device

Yael L. Maxwell

May 20, 2015

News Conference News EuroPCR 2014

Benefit of LAA Closure Becomes Most Evident After 1 Year

Caitlin E. Cox

May 23, 2014

News Conference News EuroPCR 2014

Early Data Show Novel Catheter-Implanted Device Benefits Patients with Left Heart Failure

Caitlin E. Cox

May 22, 2014

Presentation EuroPCR 2014

Two-year clinical outcome after left atrial appendage closure with the Amplatzer Cardiac Plug device in patients with non-valvular atrial fibrillation and contraindications for anticoagulation therapy

Presenter: Jos? Ram?n L?pez-M?nguez

May 21, 2014

News Conference News EuroPCR 2013

Registry Questions Superiority of Bivalirudin Over Heparin Alone in NSTE-ACS

Yael L. Maxwell

May 23, 2013

Advertisement

LAA Closure May Provide Solution for Stroke Prevention in Patients With Prior Intracerebral Hemorrhage

Last Window for BMS Closes as LEADERS-FREE Supports DES in High-Bleeding-Risk ACS

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

‘Signal’ of Poor Durability Seen With First-Generation TAVR Devices

DEFLECT III: 30-Day Results Show Successful, Safe TAVR With Novel Neuroprotection Device

Benefit of LAA Closure Becomes Most Evident After 1 Year

Early Data Show Novel Catheter-Implanted Device Benefits Patients with Left Heart Failure

Two-year clinical outcome after left atrial appendage closure with the Amplatzer Cardiac Plug device in patients with non-valvular atrial fibrillation and contraindications for anticoagulation therapy

Registry Questions Superiority of Bivalirudin Over Heparin Alone in NSTE-ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content